Performance characteristics of a new levetiracetam immunoassay and method comparison with a high-performance liquid chromatography method

Therapeutic Drug Monitoring

Volumn 33, Issue 1, 2011, Pages 124-127

  Reineks, Edmunds Z ^a   Lawson, Susan E ^a   Lembright, Katherine E ^a   Wang, Sihe ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

HPLC; immunoassay; levetiracetam

Indexed keywords

ETIRACETAM;

ACCURACY; ANALYZER; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY CONTROL; REGRESSION ANALYSIS; VALIDATION STUDY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; IMMUNOASSAY; NOOTROPIC AGENTS; PIRACETAM; QUALITY CONTROL;

EID: 78751646276     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182048e05     Document Type: Article

References (10)

1. Crepeau AZ, Treiman DM. Levetiracetam: a comprehensive review. Expert Rev Neurother. 2010;10:159-171.
2. Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239-1276.
3. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347-363.
4. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs-when is monitoring needed? Clin Pharmacokinet. 2006;45:1061-1075.
5. Contin M, Mohamed S, Albani F, et al. Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy. J Chromatogr B Biomed Sci App. 2008;873:129-132.
6. Lancelin F, Franchon E, Kraoul L, et al. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodi-ode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. Ther Drug Monit. 2007;29:576-583.
7. Juenke JM, Brown PI, Urry FM, et al. Drug monitoring and toxicology: a procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV. J Anal Toxicol. 2006;30:27-30.
8. Tang PH, Miles MV. Rapid monitoring of levetiracetam in plasma and saliva by high-performance liquid chromatography. Ther Drug Monit. 2005;27:174.
9. Pucci V, Bugamelli F, Mandrioli R, et al. High-performance liquid chromatographic determination of levetiracetam in human plasma: comparison of different sample clean-up procedures. Biomed Chromatogr. 2004;18:37-44.
10. Ratnaraj N, Doheny HC, Patsalos PN. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography. Ther Drug Monit. 1996;18:154-157.